AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline
Executive Summary
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.
You may also be interested in...
AstraZeneca’s Enthusiasm For Vaccines On The Wane
As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.
Daiichi Sankyo/AstraZeneca Get Two Lucky Breaks For Enhertu
The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.
Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval
AstraZeneca and partner Daiichi Sankyo obtain the first approval for targeted therapy in HER2-low metastatic breast cancer for Enhertu, about four months ahead of the FDA action date.